Chronic neutrophilic leukemia interventions: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) |
m (Bot: Removing from Primary care) |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chronic neutrophilic leukemia}} | {{Chronic neutrophilic leukemia}} | ||
{{CMG}}; | {{CMG}}; {{AE}} {{Homa}}; {{GRR}} {{Nat}} | ||
==Overview== | ==Overview== | ||
[[Hematopoietic stem cell transplantation|Hematopoitic stem cell transplant]] is the mainstay of treatment for CNL patients. It is recommended that every [[Patient|patients]] that are qualified for HSCT, take this treatment. Since, the therapy in [[blast]] phases has the poor [[outcome]]<nowiki/>s, HSCT should be started as soon as possible in the [[disease]] course, before [[blast]] [[transformation]]. [[Splenic]] irradiation was used as a [[palliative]] [[treatment]] in [[patient]]<nowiki/>s of CNL with [[splenomegaly]]. | |||
[ | |||
==Indications== | ==Indications== | ||
*<nowiki/>[[Hematopoietic stem cell transplantation|Hematopoitic stem cell transplant]] (HSCT): HSCT is the only potential therapeutic option for patients with CNL. It is recommended that every [[Patient|patients]] that are qualified for HSCT, take this treatment. Since, the therapy in [[blast]] phases has the poor [[outcome]]<nowiki/>s, HSCT should be started as soon as possible in the [[disease]] course, before [[blast]] [[transformation]].<ref name="ElliottHanson2004">{{cite journal|last1=Elliott|first1=M A|last2=Hanson|first2=C A|last3=Dewald|first3=G W|last4=Smoley|first4=S A|last5=Lasho|first5=T L|last6=Tefferi|first6=A|title=WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature|journal=Leukemia|volume=19|issue=2|year=2004|pages=313–317|issn=0887-6924|doi=10.1038/sj.leu.2403562}}</ref><ref name="KakoKanda2007">{{cite journal|last1=Kako|first1=Shinichi|last2=Kanda|first2=Yoshinobu|last3=Sato|first3=Tomohiko|last4=Goyama|first4=Susumu|last5=Noda|first5=Naohiro|last6=Shoda|first6=Eriko|last7=Oshima|first7=Kumi|last8=Inoue|first8=Morihiro|last9=Izutsu|first9=Koji|last10=Watanabe|first10=Takuro|last11=Motokura|first11=Toru|last12=Chiba|first12=Shigeru|last13=Fukayama|first13=Masashi|last14=Kurokawa|first14=Mineo|title=Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation|journal=American Journal of Hematology|volume=82|issue=5|year=2007|pages=386–390|issn=03618609|doi=10.1002/ajh.20805}}</ref><ref name="SzuberTefferi2018">{{cite journal|last1=Szuber|first1=Natasha|last2=Tefferi|first2=Ayalew|title=Chronic neutrophilic leukemia: new science and new diagnostic criteria|journal=Blood Cancer Journal|volume=8|issue=2|year=2018|issn=2044-5385|doi=10.1038/s41408-018-0049-8}}</ref><ref name="CigudosaMenezes2015">{{cite journal|last1=Cigudosa|first1=Juan C|last2=Menezes|first2=Juliane|title=Chronic neutrophilic leukemia: a clinical perspective|journal=OncoTargets and Therapy|year=2015|pages=2383|issn=1178-6930|doi=10.2147/OTT.S49688}}</ref><ref name="TabbaraZimmerman2002">{{cite journal|last1=Tabbara|first1=Imad A.|last2=Zimmerman|first2=Kathy|last3=Morgan|first3=Connie|last4=Nahleh|first4=Zeina|title=Allogeneic Hematopoietic Stem Cell Transplantation|journal=Archives of Internal Medicine|volume=162|issue=14|year=2002|pages=1558|issn=0003-9926|doi=10.1001/archinte.162.14.1558}}</ref> | |||
*[[Hematopoietic stem cell transplantation|Hematopoitic stem cell transplant]] (HSCT): HSCT is the only potential therapeutic option for patients with CNL. It is recommended that every [[Patient|patients]] that are qualified for HSCT, take this treatment. Since, the therapy in [[blast]] phases has the poor [[outcome]]<nowiki/>s, HSCT should be started as soon as possible in the disease course, before blast transformation.<ref name="ElliottHanson2004">{{cite journal|last1=Elliott|first1=M A|last2=Hanson|first2=C A|last3=Dewald|first3=G W|last4=Smoley|first4=S A|last5=Lasho|first5=T L|last6=Tefferi|first6=A|title=WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature|journal=Leukemia|volume=19|issue=2|year=2004|pages=313–317|issn=0887-6924|doi=10.1038/sj.leu.2403562}}</ref><ref name="KakoKanda2007">{{cite journal|last1=Kako|first1=Shinichi|last2=Kanda|first2=Yoshinobu|last3=Sato|first3=Tomohiko|last4=Goyama|first4=Susumu|last5=Noda|first5=Naohiro|last6=Shoda|first6=Eriko|last7=Oshima|first7=Kumi|last8=Inoue|first8=Morihiro|last9=Izutsu|first9=Koji|last10=Watanabe|first10=Takuro|last11=Motokura|first11=Toru|last12=Chiba|first12=Shigeru|last13=Fukayama|first13=Masashi|last14=Kurokawa|first14=Mineo|title=Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation|journal=American Journal of Hematology|volume=82|issue=5|year=2007|pages=386–390|issn=03618609|doi=10.1002/ajh.20805}}</ref><ref name="SzuberTefferi2018">{{cite journal|last1=Szuber|first1=Natasha|last2=Tefferi|first2=Ayalew|title=Chronic neutrophilic leukemia: new science and new diagnostic criteria|journal=Blood Cancer Journal|volume=8|issue=2|year=2018|issn=2044-5385|doi=10.1038/s41408-018-0049-8}}</ref><ref name="CigudosaMenezes2015">{{cite journal|last1=Cigudosa|first1=Juan C|last2=Menezes|first2=Juliane|title=Chronic neutrophilic leukemia: a clinical perspective|journal=OncoTargets and Therapy|year=2015|pages=2383|issn=1178-6930|doi=10.2147/OTT.S49688}}</ref> | **[[Complications]] and [[side effects]] of this [[therapy]] include: | ||
*[[Splenic]] [[irradiation]] | ***[[Infection]] | ||
***[[Veno-occlusive disease]] | |||
***Mucositis | |||
***[[Graft-versus-host disease]] (GVHD) | |||
***Graft versus tumor effect | |||
*[[Splenic]] [[irradiation]]: [[Splenic]] [[irradiation]] was used as a [[palliative]] [[treatment]] in [[patient|patien]]<nowiki/>[[patient|t]]<nowiki/>s of CNL with [[splenomegaly]].<ref>{{Cite journal | |||
| author = [[W. You]] & [[I. M. Weisbrot]] | |||
| title = Chronic neutrophilic leukemia. Report of two cases and review of the literature | |||
| journal = [[American journal of clinical pathology]] | |||
| volume = 72 | |||
| issue = 2 | |||
| pages = 233–242 | |||
| year = 1979 | |||
| month = August | |||
| pmid = 289288 | |||
}}</ref> | |||
==References== | ==References== | ||
| Line 33: | Line 32: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | |||
[[Category:Up-To-Date]] | |||
[[Category:Medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
Latest revision as of 20:57, 29 July 2020
|
Chronic neutrophilic leukemia Microchapters |
|
Differentiating Chronic neutrophilic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic neutrophilic leukemia interventions On the Web |
|
American Roentgen Ray Society Images of Chronic neutrophilic leukemia interventions |
|
Directions to Hospitals Treating Chronic neutrophilic leukemia |
|
Risk calculators and risk factors for Chronic neutrophilic leukemia interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]
Overview
Hematopoitic stem cell transplant is the mainstay of treatment for CNL patients. It is recommended that every patients that are qualified for HSCT, take this treatment. Since, the therapy in blast phases has the poor outcomes, HSCT should be started as soon as possible in the disease course, before blast transformation. Splenic irradiation was used as a palliative treatment in patients of CNL with splenomegaly.
Indications
- Hematopoitic stem cell transplant (HSCT): HSCT is the only potential therapeutic option for patients with CNL. It is recommended that every patients that are qualified for HSCT, take this treatment. Since, the therapy in blast phases has the poor outcomes, HSCT should be started as soon as possible in the disease course, before blast transformation.[1][2][3][4][5]
- Complications and side effects of this therapy include:
- Infection
- Veno-occlusive disease
- Mucositis
- Graft-versus-host disease (GVHD)
- Graft versus tumor effect
- Complications and side effects of this therapy include:
- Splenic irradiation: Splenic irradiation was used as a palliative treatment in patients of CNL with splenomegaly.[6]
References
- ↑ Elliott, M A; Hanson, C A; Dewald, G W; Smoley, S A; Lasho, T L; Tefferi, A (2004). "WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature". Leukemia. 19 (2): 313–317. doi:10.1038/sj.leu.2403562. ISSN 0887-6924.
- ↑ Kako, Shinichi; Kanda, Yoshinobu; Sato, Tomohiko; Goyama, Susumu; Noda, Naohiro; Shoda, Eriko; Oshima, Kumi; Inoue, Morihiro; Izutsu, Koji; Watanabe, Takuro; Motokura, Toru; Chiba, Shigeru; Fukayama, Masashi; Kurokawa, Mineo (2007). "Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation". American Journal of Hematology. 82 (5): 386–390. doi:10.1002/ajh.20805. ISSN 0361-8609.
- ↑ Szuber, Natasha; Tefferi, Ayalew (2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer Journal. 8 (2). doi:10.1038/s41408-018-0049-8. ISSN 2044-5385.
- ↑ Cigudosa, Juan C; Menezes, Juliane (2015). "Chronic neutrophilic leukemia: a clinical perspective". OncoTargets and Therapy: 2383. doi:10.2147/OTT.S49688. ISSN 1178-6930.
- ↑ Tabbara, Imad A.; Zimmerman, Kathy; Morgan, Connie; Nahleh, Zeina (2002). "Allogeneic Hematopoietic Stem Cell Transplantation". Archives of Internal Medicine. 162 (14): 1558. doi:10.1001/archinte.162.14.1558. ISSN 0003-9926.
- ↑ W. You & I. M. Weisbrot (1979). "Chronic neutrophilic leukemia. Report of two cases and review of the literature". American journal of clinical pathology. 72 (2): 233–242. PMID 289288. Unknown parameter
|month=ignored (help)